Compare IMXI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | URGN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | IMXI | URGN |
|---|---|---|
| Price | $15.36 | $22.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $16.67 | ★ $28.50 |
| AVG Volume (30 Days) | 241.4K | ★ 888.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $625,123,000.00 | $96,516,000.00 |
| Revenue This Year | N/A | $27.96 |
| Revenue Next Year | $0.95 | $123.02 |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | N/A | ★ 8.00 |
| 52 Week Low | $8.58 | $3.42 |
| 52 Week High | $21.41 | $30.00 |
| Indicator | IMXI | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 47.75 |
| Support Level | $15.35 | $21.62 |
| Resistance Level | $15.51 | $24.71 |
| Average True Range (ATR) | 0.06 | 1.54 |
| MACD | -0.02 | -0.38 |
| Stochastic Oscillator | 39.62 | 18.53 |
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.